Lisa J Russell1, Amir Enshaei, Lisa Jones, Amy Erhorn, Dino Masic, Helen Bentley, Karl S Laczko, Adele K Fielding, Anthony H Goldstone, Nicholas Goulden, Christopher D Mitchell, Rachel Wade, Ajay Vora, Anthony V Moorman, Christine J Harrison. 1. Lisa J. Russell, Amir Enshaei, Lisa Jones, Amy Erhorn, Dino Masic, Helen Bentley, Anthony V. Moorman, and Christine J. Harrison, Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne; Karl S. Laczko, Leica Microsystems, Gateshead; Adele K. Fielding, Royal Free and University College London Medical School; Anthony H. Goldstone, University College London Hospital; Nicholas Goulden, Great Ormond St Hospital, London; Christopher D. Mitchell, John Radcliffe Hospital; Rachel Wade, Clinical Trial Service Unit, University of Oxford, Oxford; and Ajay Vora, Sheffield Children's Hospital, Sheffield, United Kingdom.
Abstract
PURPOSE: To determine the prevalence and prognostic association of immunoglobulin heavy chain (IGH@) translocations in acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: The cohort comprised 3,269 patients treated on either the UKALL2003 trial for children and adolescents (1 to 24 years old) or the UKALLXII trial for adolescents and adults (15 to 59 years old). High-throughput fluorescent in situ hybridization was used to detect IGH@ translocations. RESULTS: We identified IGH@ translocations in 5% of patients with ALL (159 of 3,269 patients), in patients with both B-cell (148 of 2,863 patients) and T-cell (11 of 408 patients) disease. Multiple partner genes were identified including CRLF2 (n = 35), five members of the CEPB gene family (n = 17), and ID4 (n = 11). The level of the IGH@-positive clone varied and indicated that some IGH@ translocations were primary events, whereas others were secondary aberrations often associated with other established aberrations. The age profile of patients with IGH@ translocations was distinctive, with a median age of 16 years and peak incidence of 11% among 20- to 24-year-old patients. Among patients with B-cell precursor ALL who were Philadelphia chromosome negative, those with an IGH@ translocation had an inferior overall survival compared with other patients (UKALL2003: hazard ratio, 2.37; 95% CI, 1.34 to 4.18; P = .003; UKALLXII: hazard ratio, 1.73; 95% CI, 1.22 to 2.47; P = .002). However, this adverse effect was not independent of age or minimal residual disease status and did not seem to be driven by an increased risk of relapse. CONCLUSION: IGH@ translocations define a genetic feature that is frequent among adolescents and young adults with ALL. Although associated with an adverse outcome in adults, it is not an independent prognostic factor in children and adolescents.
PURPOSE: To determine the prevalence and prognostic association of immunoglobulin heavy chain (IGH@) translocations in acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: The cohort comprised 3,269 patients treated on either the UKALL2003 trial for children and adolescents (1 to 24 years old) or the UKALLXII trial for adolescents and adults (15 to 59 years old). High-throughput fluorescent in situ hybridization was used to detect IGH@ translocations. RESULTS: We identified IGH@ translocations in 5% of patients with ALL (159 of 3,269 patients), in patients with both B-cell (148 of 2,863 patients) and T-cell (11 of 408 patients) disease. Multiple partner genes were identified including CRLF2 (n = 35), five members of the CEPB gene family (n = 17), and ID4 (n = 11). The level of the IGH@-positive clone varied and indicated that some IGH@ translocations were primary events, whereas others were secondary aberrations often associated with other established aberrations. The age profile of patients with IGH@ translocations was distinctive, with a median age of 16 years and peak incidence of 11% among 20- to 24-year-old patients. Among patients with B-cell precursor ALL who were Philadelphia chromosome negative, those with an IGH@ translocation had an inferior overall survival compared with other patients (UKALL2003: hazard ratio, 2.37; 95% CI, 1.34 to 4.18; P = .003; UKALLXII: hazard ratio, 1.73; 95% CI, 1.22 to 2.47; P = .002). However, this adverse effect was not independent of age or minimal residual disease status and did not seem to be driven by an increased risk of relapse. CONCLUSION: IGH@ translocations define a genetic feature that is frequent among adolescents and young adults with ALL. Although associated with an adverse outcome in adults, it is not an independent prognostic factor in children and adolescents.
Authors: Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger Journal: Blood Date: 2017-04-13 Impact factor: 22.113
Authors: Jinghui Zhang; Kelly McCastlain; Hiroki Yoshihara; Beisi Xu; Yunchao Chang; Michelle L Churchman; Gang Wu; Yongjin Li; Lei Wei; Ilaria Iacobucci; Yu Liu; Chunxu Qu; Ji Wen; Michael Edmonson; Debbie Payne-Turner; Kerstin B Kaufmann; Shin-Ichiro Takayanagi; Erno Wienholds; Esmé Waanders; Panagiotis Ntziachristos; Sofia Bakogianni; Jingjing Wang; Iannis Aifantis; Kathryn G Roberts; Jing Ma; Guangchun Song; John Easton; Heather L Mulder; Xiang Chen; Scott Newman; Xiaotu Ma; Michael Rusch; Pankaj Gupta; Kristy Boggs; Bhavin Vadodaria; James Dalton; Yanling Liu; Marcus L Valentine; Li Ding; Charles Lu; Robert S Fulton; Lucinda Fulton; Yashodhan Tabib; Kerri Ochoa; Meenakshi Devidas; Deqing Pei; Cheng Cheng; Jun Yang; William E Evans; Mary V Relling; Ching-Hon Pui; Sima Jeha; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Guido Marcucci; Clara D Bloomfield; Jessica Kohlschmidt; Krzysztof Mrózek; Elisabeth Paietta; Martin S Tallman; Wendy Stock; Matthew C Foster; Janis Racevskis; Jacob M Rowe; Selina Luger; Steven M Kornblau; Sheila A Shurtleff; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; John E Dick; Stephen P Hunger; Mignon L Loh; James R Downing; Charles G Mullighan Journal: Nat Genet Date: 2016-10-24 Impact factor: 38.330
Authors: Moneeb A K Othman; Beata Grygalewicz; Barbara Pienkowska-Grela; Jolanta Rygier; Anna Ejduk; Martina Rincic; Joana B Melo; Isabel M Carreira; Britta Meyer; Thomas Liehr Journal: Oncol Lett Date: 2016-01-29 Impact factor: 2.967
Authors: Rabea Wagener; Cristina López; Kortine Kleinheinz; Julia Bausinger; Sietse M Aukema; Inga Nagel; Umut H Toprak; Julian Seufert; Janine Altmüller; Holger Thiele; Christof Schneider; Julia Kolarova; Jeongbin Park; Daniel Hübschmann; Eva M Murga Penas; Hans G Drexler; Andishe Attarbaschi; Randi Hovland; Eigil Kjeldsen; Michael Kneba; Udo Kontny; Laurence de Leval; Peter Nürnberg; Ilske Oschlies; David Oscier; Brigitte Schlegelberger; Stephan Stilgenbauer; Wilhelm Wössmann; Matthias Schlesner; Birgit Burkhardt; Wolfram Klapper; Elaine S Jaffe; Ralf Küppers; Reiner Siebert Journal: Blood Date: 2018-10-03 Impact factor: 22.113